A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial(†)

BACKGROUND: This double-blind, phase 3 study assessed the efficacy and safety of ganitumab combined with gemcitabine as first-line treatment of metastatic pancreatic cancer. PATIENTS AND METHODS: Patients with previously untreated metastatic pancreatic adenocarcinoma were randomly assigned 2 : 2 : 1...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Ann Oncol
Main Authors: Fuchs, C. S., Azevedo, S., Okusaka, T., Van Laethem, J.-L., Lipton, L. R., Riess, H., Szczylik, C., Moore, M. J., Peeters, M., Bodoky, G., Ikeda, M., Melichar, B., Nemecek, R., Ohkawa, S., Świeboda-Sadlej, A., Tjulandin, S. A., Van Cutsem, E., Loberg, R., Haddad, V., Gansert, J. L., Bach, B. A., Carrato, A.
פורמט: Artigo
שפה:Inglês
יצא לאור: Oxford University Press 2015
נושאים:
Original Articles
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4804122/
https://ncbi.nlm.nih.gov/pubmed/25609246
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdv027
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים